TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Silexion Therapeutics ( (SLXN) ) has provided an announcement.
At the extraordinary general meeting of Silexion Therapeutics Corp, originally held on August 12, 2025, and reconvened on August 19, 2025, the shareholders approved a resolution to amend the company’s memorandum of association, increasing the authorized share capital. During the reconvened meeting, a quorum was established with 16.8% of the company’s shares represented, and the proposal to increase the share capital from US$20,000 to US$121,500 was approved by a simple majority, with 59.8% voting in favor.
The most recent analyst rating on (SLXN) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.
Spark’s Take on SLXN Stock
According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.
Silexion Therapeutics has significant financial difficulties with zero revenue and negative equity, posing major risks. Technical analysis indicates a bearish trend, and speculative valuation metrics reflect the high-risk nature of the stock. However, promising corporate developments, such as the SIL204 partnership and positive preclinical results, offer potential upside if clinical success is achieved.
To see Spark’s full report on SLXN stock, click here.
More about Silexion Therapeutics
Average Trading Volume: 91,288
Technical Sentiment Signal: Sell
Current Market Cap: $5.3M
Learn more about SLXN stock on TipRanks’ Stock Analysis page.